Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial
Authors
Keywords
-
Journal
Lancet Gastroenterology & Hepatology
Volume 8, Issue 6, Pages 511-522
Publisher
Elsevier BV
Online
2023-03-17
DOI
10.1016/s2468-1253(23)00068-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Mechanisms and possible hepatoprotective effects of glucagon-like peptide-1 receptor agonists and other incretin receptor agonists in non-alcoholic fatty liver disease
- (2023) Giovanni Targher et al. Lancet Gastroenterology & Hepatology
- A Machine Learning Approach Enables Quantitative Measurement of Liver Histology and Disease Monitoring in NASH
- (2021) Amaro Taylor‐Weiner et al. HEPATOLOGY
- Once-Weekly Semaglutide in Adults with Overweight or Obesity
- (2021) John P.H. Wilding et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mechanisms and disease consequences of nonalcoholic fatty liver disease
- (2021) Rohit Loomba et al. CELL
- Glycemic Control Predicts Severity of Hepatocyte Ballooning and Hepatic Fibrosis in Nonalcoholic Fatty Liver Disease
- (2021) Anastasia‐Stefania Alexopoulos et al. HEPATOLOGY
- Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis
- (2021) Alessandro Mantovani et al. Lancet Gastroenterology & Hepatology
- Longitudinal association of magnetic resonance elastography‐associated liver stiffness with complications and mortality
- (2021) Mayu Higuchi et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease
- (2021) Arun J. Sanyal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Expert Panel Review to Compare FDA and EMA Guidance on Drug Development and Endpoints in Nonalcoholic Steatohepatitis
- (2021) Rohit Loomba et al. GASTROENTEROLOGY
- Association Between Fibrosis Stage and Outcomes of Patients with Non-Alcoholic Fatty Liver Disease: a Systematic Review and Meta-Analysis
- (2020) Rod S. Taylor et al. GASTROENTEROLOGY
- Selonsertib for Patients with Bridging Fibrosis or Compensated Cirrhosis Due to NASH: Results from Randomized Ph III STELLAR Trials
- (2020) Stephen A. Harrison et al. JOURNAL OF HEPATOLOGY
- Efficacy, safety and cardiovascular outcomes of once‐daily oral semaglutide in patients with type 2 diabetes: The PIONEER programme
- (2020) Tina K. Thethi et al. DIABETES OBESITY & METABOLISM
- Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH
- (2020) Rohit Loomba et al. HEPATOLOGY
- A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis
- (2020) Philip N. Newsome et al. NEW ENGLAND JOURNAL OF MEDICINE
- Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1–7 trials
- (2019) V. R Aroda et al. DIABETES & METABOLISM
- Diabetes is Associated with Increased Risk of Hepatocellular Carcinoma in Cirrhosis Patients with Nonalcoholic Fatty Liver Disease
- (2019) Ju Dong Yang et al. HEPATOLOGY
- Peculiarities of Cirrhosis due to Nonalcoholic Steatohepatitis (NASH)
- (2019) Omar El-Sherif et al. SEMINARS IN LIVER DISEASE
- Obesity in the Liver Transplant Setting
- (2019) Moctezuma-Velazquez et al. Nutrients
- Simtuzumab Is Ineffective for Patients with Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis
- (2018) Stephen A. Harrison et al. GASTROENTEROLOGY
- EASL Clinical Practice Guidelines on nutrition in chronic liver disease
- (2018) Manuela Merli et al. JOURNAL OF HEPATOLOGY
- Factors Associated With Histologic Response in Adult Patients With Nonalcoholic Steatohepatitis
- (2018) Rohit Loomba et al. GASTROENTEROLOGY
- The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
- (2017) Naga Chalasani et al. HEPATOLOGY
- Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease
- (2017) Chris Estes et al. HEPATOLOGY
- EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
- (2016) JOURNAL OF HEPATOLOGY
- MRI and MRE for non-invasive quantitative assessment of hepatic steatosis and fibrosis in NAFLD and NASH: Clinical trials to clinical practice
- (2016) Parambir S. Dulai et al. JOURNAL OF HEPATOLOGY
- Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
- (2016) Matthew James Armstrong et al. LANCET
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Expanding consensus in portal hypertension
- (2015) Roberto de Franchis JOURNAL OF HEPATOLOGY
- Long-term therapy for chronic hepatitis B: Hepatitis B virus DNA suppression leading to cirrhosis reversal
- (2013) Patrick Marcellin et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now